인젝션 펜 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Injection Pen Market Summary

The global injection pen market size was valued at USD 42.5 billion in 2025 and is projected to grow from USD 45.3 billion in 2026 to USD 76.4 billion by 2033, at a CAGR of 7.7% from 2026 to 2033. North America injection pen industry held the largest share of 44.8% of the global market in 2025. A rising number of chronic diseases, such as osteoporosis, diabetes, cardiovascular disease, and multiple sclerosis, are driving the demand for injection pens.

Injector pens are ideal for chronic conditions that require frequent dosing. Another factor propelling the market is the growing utilization of innovative reusable injection pens and the growing demand for automated injection pens. Medical practitioners are turning to automated injection pens owing to their safety, simplicity, convenience, and accuracy in administering medication. A growing number of diabetic patients and their seriousness worldwide has necessitated the demand for insulin injections. For instance, according to the Institute for Health Metrics and Evaluation, over 500 million individuals globally have diabetes, impacting people of all ages and genders in every nation. This number is expected to surpass 1.3 billion in the next three decades, with diabetes becoming one of the top 10 causes of death and disability, with a current global prevalence rate of 6.1%. Moreover, sales of insulin injection pens for treating type 2 diabetes have surpassed sales of insulin vials, according to the National Institutes of Health (NIH). Injection devices are commonly utilized to self-administer insulin injections for diabetes treatment daily. Patients prefer using a pen injection method rather than a syringe to administer insulin from a vial because it is simpler. As a result, the growing occurrence of diabetes within the population has led to a rise in the use of injection pens.

The demand for injection pens has also surged due to the rising incidence of autoimmune diseases such as rheumatoid arthritis. The global prevalence of rheumatoid arthritis is approximately 0.5-1%, with biologic drugs requiring subcutaneous administration driving the adoption of injection pens. Similarly, growth hormone deficiencies, which require frequent injections, have contributed to market expansion, with pens offering better dosing accuracy and reduced administration discomfort.

Technological advancements are revolutionizing the market. Features such as dose memory, variable dosing, and ergonomic designs are enhancing patient adherence and convenience. For instance, in May 2024, the launch of Metoject Subcutaneous Injection Pen in Japan by Eisai Co., Ltd. and Nippon Medac Co., Ltd., a subsidiary of medac GmbH. This self-administrable methotrexate (MTX) pen for rheumatoid arthritis is the first of its kind in Japan. It aims to reduce patient burden and enhance the safety of self-injection. The product, available in varying dosages, received manufacturing and marketing approval in February 2024 and was added to Japan's National Health Insurance Drug Price List. With 700,000-800,000 patients with rheumatoid arthritis in Japan, this innovative pen addresses a critical therapeutic need.

The industry is witnessing significant regional expansion, driven by rising healthcare awareness and increasing prevalence of chronic diseases. In January 2024, Brazilian biopharmaceutical company Cristalia introduced a reusable pen injector for its biosimilar growth hormone, developed in collaboration with Nemera. Such partnerships highlight the focus on localized solutions to address specific market needs. In addition, rising investments in emerging markets, advancements in drug-delivery technologies, and demand for patient-friendly devices are fueling regional growth.

Global Injection Pen Market Report Segmentation

This report forecasts revenue growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global injection pen market report based on product, application, end use, and region:

• Product Outlook (Revenue, USD Billion, 2021 - 2033)
• Disposable
• Reusable
• Application Outlook (Revenue, USD Billion, 2021 - 2033)
• Diabetes
• Anaphylaxis
• Osteoporosis
• Growth Hormone Deficiency
• Arthritis
• Others
• End Use Outlook (Revenue, USD Billion, 2021 - 2033)
• Hospital
• Clinics
• Home Care Settings
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Norway
  • Denmark
  • Sweden
• Asia Pacific
  • China
  • Japan
  • South Korea
  • Thailand
  • Australia
  • India
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. End Use
  • 1.2.4. Country scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Application outlook
  • 2.2.3. End Use outlook
  • 2.2.4. Region outlook
• 2.3. Competitive Insights

Chapter 3. Injection Pen Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Injection Pen Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Injection Pen Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Injection Pen Market: Product Movement Analysis
• 4.3. Injection Pen Market by Product Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 4.5. Disposable
  • 4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Reusable
  • 4.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Injection Pen Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Injection Pen Market: Application Movement Analysis
• 5.3. Injection Pen Market by Application Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 5.5. Diabetes
  • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Anaphylaxis
  • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Osteoporosis
  • 5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Growth Hormone Deficiency
  • 5.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.9. Arthritis
  • 5.9.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.10. Others
  • 5.10.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Injection Pen Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Injection Pen Market: End Use Movement Analysis
• 6.3. Injection Pen Market by End Use Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 6.5. Hospital
  • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Clinics
  • 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Home Care Settings
  • 6.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Injection Pen Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Regional Injection Pen Market Movement Analysis
• 7.3. Injection Pen Market: Regional Estimates & Trend Analysis by Product & Application
• 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 7.5. North America
  • 7.5.1. North America Injection Pen Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. U.S.
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement scenario
    • 7.5.2.5. U.S. Injection Pen Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Canada
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement scenario
    • 7.5.3.5. Canada Injection Pen Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. Mexico
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement scenario
    • 7.5.4.5. Mexico Injection Pen Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. Europe
  • 7.5.6. Europe Injection Pen Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. UK
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Reimbursement scenario
    • 7.5.7.5. UK Injection Pen Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.8. Germany
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Competitive Scenario
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Reimbursement scenario
    • 7.5.8.5. Germany Injection Pen Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.9. France
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Competitive Scenario
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Reimbursement scenario
    • 7.5.9.5. France Injection Pen Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.10. Italy
    • 7.5.10.1. Key Country Dynamics
    • 7.5.10.2. Competitive Scenario
    • 7.5.10.3. Regulatory Framework
    • 7.5.10.4. Reimbursement scenario
    • 7.5.10.5. Italy Injection Pen Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.11. Spain
    • 7.5.11.1. Key Country Dynamics
    • 7.5.11.2. Competitive Scenario
    • 7.5.11.3. Regulatory Framework
    • 7.5.11.4. Reimbursement scenario
    • 7.5.11.5. Spain Injection Pen Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.12. Denmark
    • 7.5.12.1. Key Country Dynamics
    • 7.5.12.2. Competitive Scenario
    • 7.5.12.3. Regulatory Framework
    • 7.5.12.4. Reimbursement scenario
    • 7.5.12.5. Denmark Injection Pen Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.13. Sweden
    • 7.5.13.1. Key Country Dynamics
    • 7.5.13.2. Competitive Scenario
    • 7.5.13.3. Regulatory Framework
    • 7.5.13.4. Reimbursement scenario
    • 7.5.13.5. Sweden Injection Pen Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.14. Norway
    • 7.5.14.1. Key Country Dynamics
    • 7.5.14.2. Competitive Scenario
    • 7.5.14.3. Regulatory Framework
    • 7.5.14.4. Reimbursement scenario
    • 7.5.14.5. Norway Injection Pen Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Injection Pen Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement scenario
    • 7.6.2.5. Japan Injection Pen Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement scenario
    • 7.6.3.5. China Injection Pen Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement scenario
    • 7.6.4.5. India Injection Pen Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.5. South Korea
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement scenario
    • 7.6.5.5. South Korea Injection Pen Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.6. Australia
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement scenario
    • 7.6.6.5. Australia Injection Pen Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement scenario
    • 7.6.7.5. Thailand Injection Pen Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Injection Pen Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement scenario
    • 7.7.2.5. Brazil Injection Pen Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement scenario
    • 7.7.3.5. Argentina Injection Pen Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Middle East & Africa
  • 7.8.1. Middle East & Africa Injection Pen Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement scenario
    • 7.8.2.5. South Africa Injection Pen Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement scenario
    • 7.8.3.5. Saudi Arabia Injection Pen Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Competitive Scenario
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. Reimbursement scenario
    • 7.8.4.5. UAE Injection Pen Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Competitive Scenario
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Reimbursement scenario
    • 7.8.5.5. Kuwait Injection Pen Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Key Company Profiles
  • 8.2.1. BD
    • 8.2.1.1. Company Overview
    • 8.2.1.2. Financial Performance
    • 8.2.1.3. Product Benchmarking
    • 8.2.1.4. Strategic Initiatives
  • 8.2.2. Eli Lilly and Company
    • 8.2.2.1. Company Overview
    • 8.2.2.2. Financial Performance
    • 8.2.2.3. Product Benchmarking
    • 8.2.2.4. Strategic Initiatives
  • 8.2.3. Ypsomed AG
    • 8.2.3.1. Company Overview
    • 8.2.3.2. Financial Performance
    • 8.2.3.3. Product Benchmarking
    • 8.2.3.4. Strategic Initiatives
  • 8.2.4. Biocon
    • 8.2.4.1. Company Overview
    • 8.2.4.2. Financial Performance
    • 8.2.4.3. Product Benchmarking
    • 8.2.4.4. Strategic Initiatives
  • 8.2.5. Pfizer Inc.
    • 8.2.5.1. Company Overview
    • 8.2.5.2. Financial Performance
    • 8.2.5.3. Product Benchmarking
    • 8.2.5.4. Strategic Initiatives
  • 8.2.6. Novartis AG
    • 8.2.6.1. Company Overview
    • 8.2.6.2. Financial Performance
    • 8.2.6.3. Product Benchmarking
    • 8.2.6.4. Strategic Initiatives
  • 8.2.7. Novo Nordisk A/S
    • 8.2.7.1. Company Overview
    • 8.2.7.2. Financial Performance
    • 8.2.7.3. Product Benchmarking
    • 8.2.7.4. Strategic Initiatives
  • 8.2.8. Sanofi
    • 8.2.8.1. Company Overview
    • 8.2.8.2. Financial Performance
    • 8.2.8.3. Product Benchmarking
    • 8.2.8.4. Strategic Initiatives
  • 8.2.9. Owen Mumford Ltd.
    • 8.2.9.1. Company Overview
    • 8.2.9.2. Financial Performance
    • 8.2.9.3. Product Benchmarking
    • 8.2.9.4. Strategic Initiatives
  • 8.2.10. Merck KGaA
    • 8.2.10.1. Company Overview
    • 8.2.10.2. Financial Performance
    • 8.2.10.3. Product Benchmarking
    • 8.2.10.4. Strategic Initiatives